Yongcheng Zhang

Yongcheng Zhang

Auto-generated profile, based on publicly available information

Yongcheng Zhang

Department of Breast Care Surgery, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, China

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2002 in Asian-Australasian Journal of Animal Sciences
Verified
Journal Article
Open access
PDF file
YZYongcheng Zhang
Yongcheng Zhang
DLDefa Li
Defa Li
SFShijun Fan
Shijun Fan
XPXiangshu Piao
Xiangshu Piao
JWJitan Wang
Jitan Wang
IHIn K. Han
In K. Han

1 November 2024 in Translational Cancer Research
Verified
Journal Article
Open access
PDF file
YZYifan Zheng
Yifan Zheng
YLYufeng Lin
Yufeng Lin
YZYongcheng Zhang
Yongcheng Zhang
SLShangjie Liu
Shangjie Liu
YYYongxia Yang
Yongxia Yang
WHWenbin Huang
Wenbin Huang
Background: Disulfidptosis is a novel form of cell death triggered by disulfide stress that may have important implications for breast cancer (BC) pathogenesis. Nevertheless, studies identifying disulfidptosis-associated long non-coding RNAs (lncRNAs) in BC have not been reported. This study aimed to investigate the prognostic potential of disulfidptosis-related lncRNAs in BC. Methods: RNA-sequencing data and clinical information of BC patients were obtained from The Cancer Genome Atlas (TCGA) database. The lncRNAs associated with disulfidptosis were identified through co-expression analysis. Subsequently, a risk signature consisting of 10 lncRNAs was constructed using univariate Cox and least absolute shrinkage and selection operator (LASSO) analyses, and its predictive power was validated. Results: The risk signature was found to be an independent prognostic factor for BC patients. Notably, the two subgroups defined by the risk signature exhibited different mutant gene profiles, and risk scores were significantly correlated with tumor mutation burden (TMB). Additionally, single-sample gene set enrichment analysis (ssGSEA) and immune checkpoint analyses indicated that the predicted trait was significantly associated with the immune status of BC patients. Furthermore, 55 potential anticancer drugs were identified that were associated with the signature. Conclusions: In this study, we successfully developed a prognostic model based on disulfidptosis-related lncRNAs, which enhances the accuracy of predicting the prognosis of BC patients. This model also offers a potential target and theoretical foundation for BC treatment, laying a robust groundwork for future research on the functional roles of disulfidptosis-associated lncRNAs in BC.